Vivo Capital Fund VIII, L.P. 4
4 · Terns Pharmaceuticals, Inc. · Filed Apr 3, 2024
Insider Transaction Report
Form 4
Vivo Opportunity, LLC
10% Owner
Transactions
- Sale
Common Stock
2024-04-01$6.99/sh−5,451$38,102→ 275,772 total(indirect: By: Vivo Capital Surplus Fund VIII, L.P.) - Sale
Common Stock
2024-04-02$6.65/sh−76,346$507,701→ 4,127,611 total(indirect: By Vivo Opportunity Fund Holdings, L.P.) - Sale
Common Stock
2024-04-02$6.65/sh−22,084$146,859→ 1,975,062 total(indirect: By: Vivo Capital Fund VIII, L.P.) - Sale
Common Stock
2024-04-01$6.99/sh−39,411$275,483→ 1,997,146 total(indirect: By: Vivo Capital Fund VIII, L.P.) - Sale
Common Stock
2024-04-01$6.99/sh−136,255$952,422→ 4,203,957 total(indirect: By Vivo Opportunity Fund Holdings, L.P.) - Sale
Common Stock
2024-04-02$6.65/sh−3,050$20,283→ 272,722 total(indirect: By: Vivo Capital Surplus Fund VIII, L.P.) - Sale
Common Stock
2024-04-03$6.20/sh−103,870$643,994→ 4,023,741 total(indirect: By Vivo Opportunity Fund Holdings, L.P.) - Sale
Common Stock
2024-04-03$6.20/sh−30,047$186,291→ 1,945,015 total(indirect: By: Vivo Capital Fund VIII, L.P.) - Sale
Common Stock
2024-04-03$6.20/sh−4,149$25,724→ 268,573 total(indirect: By: Vivo Capital Surplus Fund VIII, L.P.)
Footnotes (7)
- [F1]The shares are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the General Partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F2]The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F3]The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F4]The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2023.
- [F5]The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.71 to $7.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.
- [F6]The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4.
- [F7]The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $5.97 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (7) to this Form 4.